AMDM Focus Meeting October 5-6, 2017

AMDM 2017 Focus Meeting



Day 1	Thursday October 5 th Agenda	- MARK
8:00 – 8:30 am	Registration / Continental Breakfast / Welcome Event Co-Chairs: Liz Lison, Tiffany Levin	Room: Ballroom
8:30 – 9:00	FDA Update and Q&A via video link Elizabeth Hillebrenner, Associate Director for Programs and Performance, CDRH/OIR	
9:00 – 9:30	Industry Update Robert Di Tullio, Beaufort	
9:30 – 10:30	FDA's Cybersecurity Guidance and Approach to Cloud Computing Aftin Ross, Office of the Center Director, CDRH via video link	
10:30 - 11:00	Break	
11:00 - 11:30	Practical application of the FDA's Cybersecurity Guidance John Roche, RBC Group	
11:30 – 12:00	RFID Product Labeling – The New Generation of Automatic Identification Josh Miller, Computype	
12:00 – 12:30	How to Comment on FDA Guidance Documents Allyson Mullen, Hyman, Phelps & McNamara	
12:30 - 1:30	Lunch	
1:30 – 2:00	The FDA's New Digital Health Program Joel Centeno, Goldbug Strategies	
2:00 – 2:30	CE Marking of Clinical Trial Assays Stewart McWilliams, VP RA/QA, Almac Diagnostics	
2:30 – 3:00	A Review of the CDx Process in Japan and China Xiaolei Xu, Sr. Manager RA, Agilent Technologies	
3:00 - 3:15	Break	
3:15 – 3:45	The 510(k) Exempt Sphere Grows Erika Ammirati, Owner, Ammirati Consulting	

AMDM Focus Meeting October 5-6, 2017

AMDM 2017 Focus Meeting

Day 1 / Thursday October 5th Agenda Continued:

3:45 – 4:15	The Development of an IVD-Compliant Quality System in a CLIA QMS Background Josh Levin, Personal Genome Diagnostics (PGDx)
4:15 – 4:45	CLIA Waiver Updates James Boiani, Epstein Becker & Green / General Counsel, Coalition for CLIA Waiver Reform
4:45	Adjourn for Welcome Reception

Day 2	Friday October 6 th Agenda
8:00 – 8:30 am	Continental Breakfast / Welcome Event Co-Chairs: Liz Lison, Tiffany Levin
8:30 - 9:00	Hot Topics in Molecular Testing Donna Roscoe, CDRH/OIR via video link
9:00 – 9:30	Bridging Studies: Requirements for Demonstrating Non-Inferiority Marina Kondratovich, CDRH/OIR via video link
9:30 – 10:00	Strategies for Drug Approvals with no simultaneous CDx approval Reena Philip, CDRH/OIR via video link
10:00 - 10:30	Break & Hotel Check-Out
10:00 – 10:30 10:30 – 11:15	Break & Hotel Check-Out Companion and Complementary Diagnostics: Life after the PDL1 "Blueprint Initiative" David Stanforth, Sr. Director, CDx, Daiichi Sankyo, Inc.
	Companion and Complementary Diagnostics: Life after the PDL1 "Blueprint Initiative"
10:30 – 11:15	Companion and Complementary Diagnostics: Life after the PDL1 "Blueprint Initiative" David Stanforth, Sr. Director, CDx, Daiichi Sankyo, Inc. Oncomine Dx Target Test: Approval of an NGS CDx panel

Conference materials and an event evaluation are available at:

http://www.amdm.org/meetingmaterials.html

Password: 2017